Market Overview:
The global budesonide aerosol market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of respiratory diseases, rising awareness about asthma and other respiratory disorders, and technological advancements in the field of inhalation therapy. Based on type, the global budesonide aerosol market is segmented into 50ug/200 spray, 100ug/200 spray, 200ug/100 spray, and other segments. The 100ug/200 spray segment is expected to account for the largest share of the global budesonide aerosol market in 2018. This segment is also projected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030.
Product Definition:
Budesonide Aerosol is a corticosteroid that is used to treat asthma and other respiratory illnesses. It helps to open the airways and make breathing easier.
50ug/200 Spray:
50ug/200 Spray is a unit dosage form of buserelin, which is an anti-inflammatory and bronchodilator drug. Budesonide Aerosol (BSA) manufactured by GlaxoSmithKline (GSK)is used for the treatment of asthma in patients 12 years and older.
100ug/200 Spray:
Budesonide Aerosol is used for the treatment of asthma. The drug belongs to a group of medications called bronchodilators. Budesonide helps reduce inflammation and itching in the lungs, which may cause shortness breath and coughing.
Application Insights:
The clinics segment held the largest share of over 70.0% in 2017. Budesonide is used for the treatment of asthma and allergic rhinitis, which comprises nasal congestion and watery eyes as main symptoms. As per WHO, around 50 million people are affected by asthma across the globe, wherein about 1 out of 10 patients are receiving medical treatment due to this disease. Thus, rising prevalence along with awareness regarding early diagnosis is anticipated to fuel product demand in clinics application segment over the forecast period.
Budesonide also finds applications in ophthalmic solutions for use during eye drops administration for various indications such as allergic conjunctivitis or keratoconus-related corneal ulcers among others; however its penetration is low compared to other segments owing to high cost associated with it (400 USD).
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its dominance over the forecast period as well. This can be attributed to increasing awareness about diseases, high disposable income, and availability of advanced medical treatments along with supportive government initiatives for a healthy lifestyle.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to improving economic conditions and rising health consciousness among people in this region. In addition, increasing number of manufacturing facilities by key players for producing aerosolized budesonide tablets will also help boost demand during the forecast period from 2018 to 2030 (Ref). For instance; In May 2016; Actavis increased its production capacity for budesonide tablets by expanding its facility in China (Ref). Such factors are likely drive regional market growth over the next eight years till 2030 time frame.
In terms of revenue, Europe was valued at USD X million in 2017.
Growth Factors:
- Increasing prevalence of asthma and other respiratory diseases: The global prevalence of asthma is estimated to be around 300 million, and is expected to grow further in the coming years. This will drive the demand for budesonide aerosol, as it is one of the most effective treatments for asthma.
- Growing awareness about the benefits of budesonide aerosol: There is growing awareness among patients and healthcare professionals about the benefits of using budesonide aerosol for treating respiratory diseases. This will help boost demand for this drug in the coming years.
- Rising number of product approvals: The number of product approvals for budesonide aerosol has been increasing in recent years, due to its proven efficacy in treating respiratory diseases. This will help fuel growth in this market over the next few years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Budesonide Aerosol Market Research Report
By Type
50ug/200 Spray, 100ug/200 Spray, 200ug/100 Spray, Other
By Application
Hospitals, Clinics, Other
By Companies
AstraZeneca, Pfizer, Teva, Cipla, Novartis, Mylan, Abbott, Takeda, Boehringer Ingelheim, Allgen Pharmaceuticals, AstraZeneca, Sandoz, Shimadzu Corp, Manus Aktteva Biopharma LLP, Skyepharma, Shanghai Sine Pharmaceutical, Lunan Better Pharmaceutical, Wellcome Australia Ltd, Synmosa Biopharma Corporation, Chiesi Farmaceutici S.p.A
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
228
Number of Tables & Figures
160
Customization Available
Yes, the report can be customized as per your need.
Global Budesonide Aerosol Market Report Segments:
The global Budesonide Aerosol market is segmented on the basis of:
Types
50ug/200 Spray, 100ug/200 Spray, 200ug/100 Spray, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Pfizer
- Teva
- Cipla
- Novartis
- Mylan
- Abbott
- Takeda
- Boehringer Ingelheim
- Allgen Pharmaceuticals
- AstraZeneca
- Sandoz
- Shimadzu Corp
- Manus Aktteva Biopharma LLP
- Skyepharma
- Shanghai Sine Pharmaceutical
- Lunan Better Pharmaceutical
- Wellcome Australia Ltd
- Synmosa Biopharma Corporation
- Chiesi Farmaceutici S.p.A
Highlights of The Budesonide Aerosol Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 50ug/200 Spray
- 100ug/200 Spray
- 200ug/100 Spray
- Other
- By Application:
- Hospitals
- Clinics
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Budesonide Aerosol Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Budesonide aerosol is a medication used to treat asthma. It is a corticosteroid and works by reducing inflammation in the airways.
Some of the major players in the budesonide aerosol market are AstraZeneca, Pfizer, Teva, Cipla, Novartis, Mylan, Abbott, Takeda, Boehringer Ingelheim, Allgen Pharmaceuticals, AstraZeneca, Sandoz, Shimadzu Corp, Manus Aktteva Biopharma LLP, Skyepharma, Shanghai Sine Pharmaceutical, Lunan Better Pharmaceutical, Wellcome Australia Ltd, Synmosa Biopharma Corporation, Chiesi Farmaceutici S.p.A.
The budesonide aerosol market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Budesonide Aerosol Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Budesonide Aerosol Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Budesonide Aerosol Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Budesonide Aerosol Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Budesonide Aerosol Market Size & Forecast, 2020-2028
4.5.1 Budesonide Aerosol Market Size and Y-o-Y Growth
4.5.2 Budesonide Aerosol Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 50ug/200 Spray
5.2.2 100ug/200 Spray
5.2.3 200ug/100 Spray
5.2.4 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Budesonide Aerosol Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Budesonide Aerosol Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 50ug/200 Spray
9.6.2 100ug/200 Spray
9.6.3 200ug/100 Spray
9.6.4 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 50ug/200 Spray
10.6.2 100ug/200 Spray
10.6.3 200ug/100 Spray
10.6.4 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 50ug/200 Spray
11.6.2 100ug/200 Spray
11.6.3 200ug/100 Spray
11.6.4 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 50ug/200 Spray
12.6.2 100ug/200 Spray
12.6.3 200ug/100 Spray
12.6.4 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 50ug/200 Spray
13.6.2 100ug/200 Spray
13.6.3 200ug/100 Spray
13.6.4 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Budesonide Aerosol Market: Competitive Dashboard
14.2 Global Budesonide Aerosol Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca
14.3.2 Pfizer
14.3.3 Teva
14.3.4 Cipla
14.3.5 Novartis
14.3.6 Mylan
14.3.7 Abbott
14.3.8 Takeda
14.3.9 Boehringer Ingelheim
14.3.10 Allgen Pharmaceuticals
14.3.11 AstraZeneca
14.3.12 Sandoz
14.3.13 Shimadzu Corp
14.3.14 Manus Aktteva Biopharma LLP
14.3.15 Skyepharma
14.3.16 Shanghai Sine Pharmaceutical
14.3.17 Lunan Better Pharmaceutical
14.3.18 Wellcome Australia Ltd
14.3.19 Synmosa Biopharma Corporation
14.3.20 Chiesi Farmaceutici S.p.A
